DK1676847T3 - Polymorfe former af rifaximin som antibiotika - Google Patents

Polymorfe former af rifaximin som antibiotika

Info

Publication number
DK1676847T3
DK1676847T3 DK06004219T DK06004219T DK1676847T3 DK 1676847 T3 DK1676847 T3 DK 1676847T3 DK 06004219 T DK06004219 T DK 06004219T DK 06004219 T DK06004219 T DK 06004219T DK 1676847 T3 DK1676847 T3 DK 1676847T3
Authority
DK
Denmark
Prior art keywords
rifaximin
antibiotics
polymorphic forms
polymorphic
forms
Prior art date
Application number
DK06004219T
Other languages
English (en)
Inventor
Giuseppe C Viscomi
Manuela Campana
Dario Braga
Donatella Confortini
Vincenzo Cannata
Denis Severini
Paolo Righi
Goffredo Rosini
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33187382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1676847(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Application granted granted Critical
Publication of DK1676847T3 publication Critical patent/DK1676847T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1236—Cooking devices induction cooking plates or the like and devices to be used in combination with them adapted to induce current in a coil to supply power to a device and electrical heating devices powered in this way
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00—Heating by electric, magnetic or electromagnetic fields
    • H05B6/02—Induction heating
    • H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12—Cooking devices
    • H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1245—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements
    • H05B6/1263—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements using coil cooling arrangements

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Electromagnetism (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
DK06004219T 2003-11-07 2004-03-09 Polymorfe former af rifaximin som antibiotika DK1676847T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT002144A ITMI20032144A1 (it) 2003-11-07 2003-11-07 Forme polimorfe di rifaximina, processi per ottenerle e

Publications (1)

Publication Number Publication Date
DK1676847T3 true DK1676847T3 (da) 2009-05-11

Family

ID=33187382

Family Applications (3)

Application Number Title Priority Date Filing Date
DK06004220T DK1676848T3 (da) 2003-11-07 2004-03-09 Polymorfe former af rifaximin som antibiotika
DK06004219T DK1676847T3 (da) 2003-11-07 2004-03-09 Polymorfe former af rifaximin som antibiotika
DK04005541T DK1557421T3 (da) 2003-11-07 2004-03-09 Polymorfe form af rifaximin som antibiotikum

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK06004220T DK1676848T3 (da) 2003-11-07 2004-03-09 Polymorfe former af rifaximin som antibiotika

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK04005541T DK1557421T3 (da) 2003-11-07 2004-03-09 Polymorfe form af rifaximin som antibiotikum

Country Status (38)

Country Link
US (5) US7045620B2 (da)
EP (6) EP1676848B1 (da)
JP (5) JP2005139161A (da)
KR (4) KR20050043589A (da)
CN (4) CN1613858A (da)
AR (3) AR043547A1 (da)
AT (3) ATE421965T1 (da)
AU (2) AU2004200964A1 (da)
BR (2) BRPI0402382A (da)
CA (2) CA2460384A1 (da)
CL (1) CL2004000498A1 (da)
CO (1) CO5560083A1 (da)
CY (3) CY1108017T1 (da)
DE (4) DE602004019298D1 (da)
DK (3) DK1676848T3 (da)
ES (3) ES2320160T4 (da)
HK (3) HK1092151A1 (da)
HR (2) HRP20040265A2 (da)
IL (2) IL160798A0 (da)
IT (1) ITMI20032144A1 (da)
JO (1) JO2470B1 (da)
MA (1) MA27069A1 (da)
MD (1) MD3653G8 (da)
ME (1) ME00424B (da)
MX (2) MXPA04002353A (da)
NO (1) NO334950B1 (da)
NZ (1) NZ531622A (da)
PL (3) PL1676847T3 (da)
PT (3) PT1676848E (da)
RS (4) RS20060168A (da)
RU (1) RU2270200C2 (da)
SI (3) SI1676847T1 (da)
TN (2) TNSN04044A1 (da)
TW (1) TWI285107B (da)
UA (1) UA86384C2 (da)
WO (1) WO2005044823A2 (da)
YU (1) YU24804A (da)
ZA (1) ZA200401948B (da)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
PL1698630T3 (pl) * 2005-03-03 2014-12-31 Alfasigma Spa Nowe postacie polimorficzne rifaksyminy,sposoby ich wytwarzania i ich zastosowanie w preparatach leczniczych
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
DK2054066T3 (da) 2006-08-02 2015-06-08 Salix Pharmaceuticals Inc Fremgangsmåder til behandling af stråle-enteritis
ITMI20061692A1 (it) * 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
NZ575550A (en) * 2006-09-22 2011-12-22 Cipla Ltd Rifaximin
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
AU2016203925B2 (en) * 2007-07-06 2016-10-20 Lupin Limited Pharmaceutical compositions of rifaximin
WO2009008005A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
EP2420226B1 (en) * 2007-07-06 2020-03-04 Lupin Limited Pharmaceutical compositions of rifaximin
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
UA101829C2 (uk) * 2008-02-25 2013-05-13 Саликс Фармасьютикалз, Лтд. ФОРМА η РИФАКСИМІНУ І ЇЇ ЗАСТОСУВАННЯ В ТЕРАПЕВТИЧНІЙ ПРАКТИЦІ
DK2252148T3 (da) * 2008-02-26 2019-05-06 Salix Pharmaceuticals Ltd Fremgangsmåder til behandling af irritabel tarmsyndrom
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
US20110065741A1 (en) * 2009-02-26 2011-03-17 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (ibs)
AU2009244190B2 (en) 2008-05-07 2016-02-25 Salix Pharmaceuticals, Ltd. Methods of treating bowel disease by administering a bowel cleanser and an antibiotic
ES2496190T3 (es) 2008-09-26 2014-09-18 Aska Pharmaceutical Co., Ltd. Agente profiláctico y/o terapéutico para trastornos gastrointestinales funcionales
US7928115B2 (en) * 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
FI3628319T3 (fi) 2008-10-02 2024-03-12 Salix Pharmaceuticals Ltd Hepaattisen enkefalopatian hoito rifaksimiinilla
US20100317681A1 (en) * 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
CA2745980C (en) 2008-12-10 2017-10-31 Cipla Limited Rifaximin complexes
IT1397617B1 (it) * 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
EP3964066A1 (en) 2009-06-02 2022-03-09 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
CA2778981C (en) * 2009-10-27 2019-04-02 Lupin Limited Solid dispersion of rifaximin
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
BR112012012316A2 (pt) 2009-11-23 2016-04-26 Cipla Ltd composição farmacêutica para administração retal tópica na forma de espuma, uso de uma composição farmacêutica, método para tratamento, prevenção ou alívio de um dustúrbio no reto, cólon, íleo terminal ou ânus, processo para fabricação de uma composição farmacêutica contendo rifaximina, uso de um silicone e dispensador para composição farmacêutica
EP2401282B2 (en) † 2009-12-28 2017-01-04 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
EP3650022A1 (en) 2010-02-18 2020-05-13 Salix Pharmaceuticals, Ltd. Methods for treating rifampin resistant clostridium difficilis infections
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
BR112012030783A2 (pt) * 2010-06-03 2015-09-29 Salix Pharmaceuticals Ltd formas de rifaximina e seus usos
US8883795B2 (en) * 2010-06-16 2014-11-11 Apotex Pharmachem Inc. Polymorphic forms of Rifaximin
LT2593463T (lt) 2010-07-12 2020-08-25 Salix Pharmaceuticals, Inc. Rifaksimino kompozicijos ir jų panaudojimas
WO2012035544A2 (en) 2010-09-13 2012-03-22 Sequent Scientific Ltd. A novel polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) * 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012060675A1 (es) * 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Proceso para la preparación de rifaximina amorfa
WO2012076832A1 (en) * 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
EP2672970B1 (en) 2011-02-11 2018-08-01 Salix Pharmaceuticals, Ltd. Forms of rifaximin and uses thereof
EP2705042A1 (en) 2011-05-02 2014-03-12 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITMI20110890A1 (it) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
AU2012332211B2 (en) 2011-11-02 2016-11-24 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (IBS) and infections
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
WO2013185211A1 (en) * 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US9849090B2 (en) 2012-12-12 2017-12-26 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of rifaximin
AU2014229467A1 (en) 2013-03-15 2015-08-06 Alfa Wassermann S.P.A. Rifaximin for use in the treating of vaginal infections.
WO2014140995A2 (en) 2013-03-15 2014-09-18 Alfa Wassermann S.P.A. Method for diagnosing vaginal infections
EP2983647B1 (en) 2013-04-12 2020-09-09 Alfasigma S.p.A. Nsaid administration and related compositions, methods and systems
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
ES2621557T3 (es) * 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
US9765088B2 (en) 2014-04-19 2017-09-19 Granules India Limited Process for the preparation of rifamycin derivatives
EP3140313B1 (en) 2014-05-04 2020-02-26 Salix Pharmaceuticals, Inc. Ibs microbiota and uses thereof
SI3143027T1 (sl) 2014-05-12 2019-10-30 Alfasigma Spa Nova solvatirana kristalna oblika rifaksimina, proizvodnja, sestavki in uporaba le-teh
MX2016016458A (es) * 2014-06-30 2017-07-13 Salix Pharmaceuticals Inc Métodos para repetir tratamiento de síndrome del intestino irritable (ibs).
CN104083324B (zh) * 2014-07-10 2017-05-10 青岛动保国家工程技术研究中心有限公司 一种利福昔明的兽用悬乳剂及其制备方法和应用
EP2982764A1 (en) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification of vaginal bacteria
CN104274391B (zh) * 2014-10-08 2017-02-01 哈尔滨坤盟医药科技有限公司 一种含利福昔明的药物制剂
WO2017021975A1 (en) * 2015-08-06 2017-02-09 Msn Laboratories Private Limited Process for the preparation of crystalline forms of rifaximin
HUE044432T2 (hu) 2016-03-24 2019-10-28 Sandoz Ag Rifaximin alfá-t tartalmazó, hosszan eltartható kompozíció
ES2700423T3 (es) 2016-03-24 2019-02-15 Sandoz Ag Composición farmacéutica que contiene rifaximina alfa y delta
US9988398B2 (en) * 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
PL3518924T3 (pl) 2016-09-30 2023-01-09 Salix Pharmaceuticals, Inc. Postacie stałej dyspersji ryfaksyminy
CN106632396B (zh) * 2017-01-06 2019-01-11 成都樵枫科技发展有限公司 γ晶型利福昔明的制备方法和用途
AU2018211305B2 (en) 2017-04-26 2019-07-25 Sandoz Ag Oral dosage form comprising rifaximin in form beta
WO2019003076A1 (en) 2017-06-26 2019-01-03 Biofer S.P.A. PYRIDO-IMIDAZO-RIFAMYCIN DERIVATIVES AS ANTIBACTERIAL AGENT
CA3142214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
CA3151010A1 (en) 2019-09-24 2021-04-01 Arturo J. Angel Rifaximin liquid formulations
US20230116647A1 (en) 2020-03-24 2023-04-13 Bausch Health Ireland Limited Methods of treating covid-19 with rifaximin
WO2021229480A1 (en) * 2020-05-15 2021-11-18 Atra Pharmaceuticals Limited Polymorph of rifaximin, process for the preparation thereof and pharmaceutical composition containing rifaximin
CA3184054A1 (en) 2020-06-26 2021-12-30 Jacob Cole Targeted release rifaximin compositions
US20230398102A1 (en) 2020-10-29 2023-12-14 Bausch Health Ireland Limited Rifaximin liquid formulations for use inthe treatment of sickle cell disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241785A (en) * 1978-07-24 1980-12-30 Peerless Of America, Inc. Heat exchangers and method of making same
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
CA1215976A (en) 1984-05-15 1986-12-30 Vincenzo Cannata New process for the synthesis of imidazo rifamycins
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
IT1199413B (it) 1984-09-26 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
ATE125541T1 (de) * 1990-06-29 1995-08-15 Lepetit Spa Reine kristalline form von rifapentin.
MXPA02006660A (es) * 2000-01-07 2002-12-13 Transform Pharmaceuticals Inc Formacion, identificacion y analisis de diversas formas solidas de alto rendimiento.
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
CN100338028C (zh) * 2000-10-31 2007-09-19 山道士有限公司 盐酸文拉法辛的晶形
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20050262269A1 (en) 2004-05-20 2005-11-24 Pike Jimmy D System and method for information handling system PCI express advanced switching
PL1698630T3 (pl) 2005-03-03 2014-12-31 Alfasigma Spa Nowe postacie polimorficzne rifaksyminy,sposoby ich wytwarzania i ich zastosowanie w preparatach leczniczych
NZ575550A (en) * 2006-09-22 2011-12-22 Cipla Ltd Rifaximin
WO2008115572A1 (en) 2007-03-21 2008-09-25 Theraquest Biosciences, Inc. Methods and compositions of nsaids
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
WO2009008005A1 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
EP2420226B1 (en) 2007-07-06 2020-03-04 Lupin Limited Pharmaceutical compositions of rifaximin
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
JP2011500552A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
UA101829C2 (uk) 2008-02-25 2013-05-13 Саликс Фармасьютикалз, Лтд. ФОРМА η РИФАКСИМІНУ І ЇЇ ЗАСТОСУВАННЯ В ТЕРАПЕВТИЧНІЙ ПРАКТИЦІ

Also Published As

Publication number Publication date
KR100867751B1 (ko) 2008-11-10
DE04005541T1 (de) 2005-12-29
MD3653F2 (en) 2008-07-31
DK1676848T3 (da) 2009-05-11
EP1557421A1 (en) 2005-07-27
KR100855084B1 (ko) 2008-08-29
CO5560083A1 (es) 2005-09-30
HRP20060093B1 (hr) 2015-12-18
NO334950B1 (no) 2014-08-04
NO20061110L (no) 2006-04-19
HRP20060093A2 (en) 2006-05-31
CY1108964T1 (el) 2014-07-02
HK1092150A1 (en) 2007-02-02
US20080132530A1 (en) 2008-06-05
CL2004000498A1 (es) 2005-03-11
PL1676848T3 (pl) 2009-07-31
TWI285107B (en) 2007-08-11
EP1676847B1 (en) 2009-01-28
ATE421965T1 (de) 2009-02-15
IL160798A0 (en) 2004-08-31
DE602004006367T2 (de) 2007-09-06
PT1676847E (pt) 2009-04-09
WO2005044823A3 (en) 2005-10-27
MA27069A1 (fr) 2004-12-20
TNSN04044A1 (en) 2006-06-01
EP2208730A1 (en) 2010-07-21
ES2320160T3 (es) 2009-05-19
HRP20040265A2 (en) 2004-12-31
RS20150292A1 (en) 2015-10-30
TNSN06069A1 (en) 2007-10-03
ITMI20032144A1 (it) 2005-05-08
CN1886408A (zh) 2006-12-27
CN101260115A (zh) 2008-09-10
PL1557421T3 (pl) 2007-08-31
CA2460384A1 (en) 2005-05-07
US7915275B2 (en) 2011-03-29
MD3653G8 (ro) 2016-08-31
DE602004006367C5 (de) 2019-04-04
SI1676848T1 (sl) 2009-06-30
RS54569B1 (en) 2016-06-30
JP5635376B2 (ja) 2014-12-03
AR081992A2 (es) 2012-10-31
AU2004287601A1 (en) 2005-05-19
US8404704B2 (en) 2013-03-26
KR20070113327A (ko) 2007-11-28
EP1557421B1 (en) 2007-05-09
MXPA06002644A (es) 2006-06-06
EP1676848B1 (en) 2009-01-28
ES2320161T3 (es) 2009-05-19
JP2007509904A (ja) 2007-04-19
CY1108909T1 (el) 2014-07-02
ATE421966T1 (de) 2009-02-15
EP1676848A1 (en) 2006-07-05
KR20060110737A (ko) 2006-10-25
AU2004287601B8 (en) 2009-03-05
AU2004287601B2 (en) 2009-02-26
CA2538546A1 (en) 2005-05-19
AR043547A1 (es) 2005-08-03
JO2470B1 (en) 2009-01-20
HK1073657A1 (en) 2005-10-14
MD20060080A (en) 2006-11-30
YU24804A (sh) 2006-08-17
ES2244364T1 (es) 2005-12-16
US20050272754A1 (en) 2005-12-08
JP5199576B2 (ja) 2013-05-15
SI1676847T1 (sl) 2009-06-30
ES2244364T3 (es) 2007-12-01
DE602004006367D1 (de) 2007-06-21
KR100883216B1 (ko) 2009-02-13
ES2320160T4 (es) 2011-03-09
CA2538546C (en) 2011-04-19
CN101260114A (zh) 2008-09-10
ME00424B (me) 2011-10-10
EP2210893A1 (en) 2010-07-28
UA86384C2 (uk) 2009-04-27
RS20060168A (en) 2008-09-29
IL174271A0 (en) 2006-08-01
IL174271A (en) 2010-12-30
MXPA04002353A (es) 2005-05-11
AU2004200964A1 (en) 2005-05-26
BRPI0407149A (pt) 2006-02-07
US20050101598A1 (en) 2005-05-12
AR081991A2 (es) 2012-10-31
CN1886408B (zh) 2010-06-09
EP1676847A1 (en) 2006-07-05
CN101260114B (zh) 2012-11-28
KR20070113326A (ko) 2007-11-28
DK1557421T3 (da) 2007-09-17
JP2011046738A (ja) 2011-03-10
PT1557421E (pt) 2007-07-31
NZ531622A (en) 2004-10-29
CN101260115B (zh) 2011-11-23
US8173801B2 (en) 2012-05-08
WO2005044823A2 (en) 2005-05-19
CN1613858A (zh) 2005-05-11
RS54568B1 (en) 2016-06-30
TW200515913A (en) 2005-05-16
JP2014177500A (ja) 2014-09-25
JP2011057698A (ja) 2011-03-24
ATE361927T1 (de) 2007-06-15
CY1108017T1 (el) 2013-09-04
RU2004108953A (ru) 2005-10-27
HK1092151A1 (en) 2007-02-02
BRPI0402382A (pt) 2005-06-28
JP2005139161A (ja) 2005-06-02
RU2270200C2 (ru) 2006-02-20
SI1557421T1 (sl) 2007-08-31
RS20150291A1 (en) 2015-10-30
PT1676848E (pt) 2009-04-09
EP1682556A2 (en) 2006-07-26
US20110160449A1 (en) 2011-06-30
ZA200401948B (en) 2004-04-29
KR20050043589A (ko) 2005-05-11
BRPI0407149A8 (pt) 2019-01-15
US20120059023A1 (en) 2012-03-08
RS54571B1 (en) 2016-06-30
PL1676847T3 (pl) 2009-07-31
DE602004019298D1 (de) 2009-03-19
DE602004019296D1 (de) 2009-03-19
US7045620B2 (en) 2006-05-16

Similar Documents

Publication Publication Date Title
DK1676847T3 (da) Polymorfe former af rifaximin som antibiotika
SE0302305D0 (sv) Novel Compounds
ECSP066436A (es) Compuestos heterociclicos fusionados
IS8108A (is) Ný efnasambönd
DK1605897T3 (da) Polyethelen-glycol-link-glp-1-forbindelser
DK1828167T3 (da) Acrylamidderivater som antibiotiske midler
IS8228A (is) Ný asetídínefnasambönd
IS8089A (is) Efnasambönd
DE602004018602D1 (de) Mikrospiegel
DK1597007T3 (da) Borepatron
ATE463248T1 (de) Cephem-verbindungen
FI20030030A0 (fi) Uusia yhdisteitä
DK1667975T3 (da) En polymorf form for 3-phenylsulfonyl-8-piperazin-1-yl-quinolin
NO20055097D0 (no) Krystallinske N-formyl-hydroksylaminforbindelser
NO20031736D0 (no) Forbindelser
SE0303452D0 (sv) New compounds
DE602004028552D1 (de) Nockenwellenversteller
SE0300118D0 (sv) Novel Compounds
SE0302667D0 (sv) Novel Compounds
SE0300388D0 (sv) Novel compounds
SE0301305D0 (sv) New compounds
SE0301246D0 (sv) New compounds
SE0302368D0 (sv) New compounds
SE0300357D0 (sv) New compounds
SE0303181D0 (sv) New compounds